Myovant is preparing to seek regulatory approval for the company’s once-daily relugolix combination therapy for the treatment of uterine fibroids following positive Phase III results that showed a 71.2 percent response rate in patients.
Myovant Sciences’ combination therapy met the main goal of a late-stage study testing the treatment in women with uterine fibroids.
